QQ客服 官方微博 反馈留言

	Puerarin incorporated into a porous PLGA/TCP scaffold promotes osteogenesis in vitro and in vivo
	Huijuan Cao; Ling Li; Cuishan Huang; Keda Shi; Qinqiang Zeng; Long Li; Jing Long; Yuxiao Lai; Ling Qin; Xinluan Wang
	2017
会议日期	2017
会议地点	北京
英文摘要	Introduction: Composite scaffolds with bioactive factors have emerged as an attractive approach for bone defect repair in recent years. Our study showed that PLGA/TCP (poly lactic-co-glycolic acid and tricalcium phosphate) was a promising porous scaffold biomaterial for orthopaedics applications. Herb-derived small molecule puerarin was used in clinical for long time, demonstrated potential anti-inflammatory, osteopromotion and adipogenic suppression effects[1], evidenced by the finding in our recently finished in vitro studies. Taken together, we produced PLGA/TCP incorporation of puerarin (PLGA/TCP/Puerarin) for repairing bone defect. Methods: Puerarin was homogenized with PLGA and TCP to form a controlled puerarin-releasing scaffold (PLGA/TCP/Puerarin) with 80:20:0.5 mass ratios by low-temperature rapid-prototype 3D biospining technology. The porosity of scaffolds were analyzed by micro CT. In vitro release of puerarin was quantified by HPLC. MC3T3-E1 cells and a 3 mm diameter and 2 mm depth hole was drilled in bilateral distal femora of knee-OA rabbits to make cartilage and subchondral bone defect model by intraarticular injection of papain were used to evaluated the osteogenic and chondrogenic effects of this incorporated composite scaffolds in vitro and in vivo. Results: Our results showed that microstructure of PLGA/TCP/Puerarin scaffolds with 400-500m pore size were similar to cancellous bone of human being and its porosity was about 75%. Rapid release was the first stage before 10 days. The second stage was from 10 days to 59 days, puerarin released steadily. The third stage was from 59 days to 84 days, puerarin released a little faster than that in the second stage. Furthermore, our results confirmed PLGA/TCP/Puerarin scaffolds appeared a better biocompatibility than PLGA/TCP, and its degradation medium could promote maturation and mineralization of MC3T3-E1 through regulating osteoblastic differentiation markers (Runx2, Osterix, OPN, OC and BSP) mRNA expression and stimulating ALP activity. In in vivo study, purerarin could relieve inflammation symptom of knee OA rabbit. Meanwhile, micro-CT data demonstrated that PLGA/TCP/Purerarin could significantly enhance the BMD within scaffold implantation region and the BMD of neighbouring proximal tibia, when compared to those without implantation group. Conclusion: In this study, we presented a 3D printing osteopromotive PLGA/TCP/Purerarin composite scaffold as a bone tissue engineering product. Acknowledgements: This work was supported by Ministry of Science and Technology (Project No.2015DFG32200), Natural Science Foundation of China (Project No.81501893), Shenzhen Sino-Swiss Science and Technology Cooperation Project (Project No.GJHZ20150316143827260) and Shenzhen Fundamental Research Foundation (Project No. JCYJ20160229195715386). References: [1] Zhou YX, Zhang H, Peng C. Puerarin: A Review of Pharmacological Effects. Phytother Res 2014;28:961-975.
语种	英语
内容类型	会议论文
源URL	[http://ir.siat.ac.cn:8080/handle/172644/12248]
专题	深圳先进技术研究院_医工所
作者单位	2017
推荐引用方式 GB/T 7714	Huijuan Cao,Ling Li,Cuishan Huang,et al. Puerarin incorporated into a porous PLGA/TCP scaffold promotes osteogenesis in vitro and in vivo[C]. 见:. 北京. 2017.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。